text_1: Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.
text_2: Inhibition of HDAC6 activity using a clinically applicable small-molecule inhibitor significantly improved the survival of mice bearing ARID1A-mutated tumours.